Vivos Therapeutics Inc
NASDAQ:VVOS
Vivos Therapeutics Inc
Cash Equivalents
Vivos Therapeutics Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
Cash Equivalents
$1.6m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Cash Equivalents
$345.1m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash Equivalents
$474m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
CVS Health Corp
NYSE:CVS
|
Cash Equivalents
$9.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Cigna Corp
NYSE:CI
|
Cash Equivalents
$8.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash Equivalents
$99.3m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-12%
|
See Also
What is Vivos Therapeutics Inc's Cash Equivalents?
Cash Equivalents
1.6m
USD
Based on the financial report for Dec 31, 2023, Vivos Therapeutics Inc's Cash Equivalents amounts to 1.6m USD.
What is Vivos Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
6%
Over the last year, the Cash Equivalents growth was -53%. The average annual Cash Equivalents growth rates for Vivos Therapeutics Inc have been -55% over the past three years , 6% over the past five years .